<DOC>
	<DOC>NCT01918865</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Body mass index (BMI) &gt;/= 27 kg/m2 HbA1c between 7.5% and 10.5% (inclusive) CPeptide (fasting) greater than or equal to 500 pmol/L On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for &gt;/= 3 months prior to screening, and remain on stable dose throughout the study Agree to conduct homebased (fasted) blood glucose testing as directed Clinically significant abnormalities in medical history or physical exam Serum creatinine &gt; ULN at Screening Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST &gt; 1.5x ULN at Screening History of renal transplantation or renal dialysis GFR &lt; 60 mL/min at Screening History of diabetic ketoacidosis History of greater than 3 episodes of severe hypoglycemia within 6 months of screening Allergy to sulfur containing drugs Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines Any other significant illness or condition that may interfere with the patient participating or completing the study Inability or unwillingness to comply with protocol or study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>T2DM</keyword>
</DOC>